Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
Artiva Biotherapeutics (Nasdaq: ARTV) has announced its participation in the upcoming Jefferies London Healthcare Conference. The company's management will engage in a fireside chat on November 20, 2024, at 3:30 p.m. GMT in London. The clinical-stage biotechnology company, focused on developing cell therapies for autoimmune diseases and cancers, will make the session available via live webcast through their website's Investor section. Management team members will also conduct in-person meetings with registered conference attendees. A replay of the webcast will remain accessible for 90 days post-event.
Artiva Biotherapeutics (Nasdaq: ARTV) ha annunciato la sua partecipazione alla prossima Conferenza Sanitaria di Jefferies a Londra. Il management dell'azienda parteciperà a una chiacchierata informale il 20 novembre 2024, alle 15:30 GMT a Londra. L'azienda biotecnologica in fase clinica, focalizzata nello sviluppo di terapie cellulari per malattie autoimmuni e tumori, renderà disponibile la sessione tramite webcast dal vivo nella sezione Investor del loro sito web. I membri del team di gestione condurranno anche incontri di persona con i partecipanti registrati alla conferenza. Una registrazione del webcast sarà accessibile per 90 giorni dopo l'evento.
Artiva Biotherapeutics (Nasdaq: ARTV) ha anunciado su participación en la próxima Conferencia de Salud de Jefferies en Londres. La dirección de la compañía participará en una charla informal el 20 de noviembre de 2024, a las 3:30 p.m. GMT en Londres. La empresa de biotecnología en etapa clínica, centrada en desarrollar terapias celulares para enfermedades autoinmunitarias y cánceres, hará que la sesión esté disponible a través de un webcast en vivo en la sección para inversores de su sitio web. Los miembros del equipo directivo también llevarán a cabo reuniones en persona con los asistentes registrados a la conferencia. Una repetición del webcast estará accesible durante 90 días después del evento.
Artiva Biotherapeutics (Nasdaq: ARTV)는 다가오는 제퍼리스 런던 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사 관리팀은 2024년 11월 20일 오후 3시 30분 GMT에 런던에서 화상 대화에 참여할 예정입니다. 자가면역 질환 및 암을 위한 세포 치료제 개발에 집중하는 임상 단계의 생명공학 회사는 자사의 웹사이트의 투자자 섹션을 통해 생방송으로 세션을 제공할 것입니다. 관리 팀의 구성원들은 등록된 컨퍼런스 참석자들과 대면 회의도 진행할 예정입니다. 웹캐스트의 재생은 이벤트 종료 후 90일 동안 이용 가능합니다.
Artiva Biotherapeutics (Nasdaq: ARTV) a annoncé sa participation à la prochaine Conférence sur la Santé de Jefferies à Londres. La direction de l'entreprise participera à une discussion informelle le 20 novembre 2024 à 15h30 GMT à Londres. La société biopharmaceutique en phase clinique, spécialisée dans le développement de thérapies cellulaires pour les maladies auto-immunes et les cancers, mettra la session à disposition via un webinaire en direct dans la section Investisseur de son site Web. Les membres de l'équipe de direction organiseront également des réunions en personne avec les participants enregistrés à la conférence. Un enregistrement du webinaire sera accessible pendant 90 jours après l'événement.
Artiva Biotherapeutics (Nasdaq: ARTV) hat seine Teilnahme an der bevorstehenden Jefferies London Healthcare Conference bekannt gegeben. Das Management des Unternehmens wird am 20. November 2024 um 15:30 Uhr GMT in London an einem informellen Gespräch teilnehmen. Das biopharmazeutische Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Zelltherapien für autoimmune Erkrankungen und Krebs spezialisiert hat, wird die Sitzung über einen Live-Webcast in der Investoren-Sektion ihrer Website zur Verfügung stellen. Mitglieder des Managementteams werden auch persönliche Meetings mit registrierten Konferenzteilnehmern durchführen. Eine Wiederholung des Webcasts wird 90 Tage nach der Veranstaltung zugänglich sein.
- None.
- None.
SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 3:30 p.m. GMT, in London, UK.
Members of the Artiva management team will also be available to participate in in-person investor meetings with investors who are registered to attend the conference.
Investors and the general public are invited to listen to a live webcast of the fireside chat through the "Investors" section on Artivabio.com. A webcast replay will be made available following the event for 90 days.
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK®, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK® is currently in clinical trials for treatment of systemic lupus erythematosus, for patients with or without lupus nephritis, and in an investigator-initiated basket trial in multiple autoimmune indications. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.
Artiva is headquartered in San Diego, California. For more information, please visit https://www.artivabio.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding upcoming events or Artiva Biotherapeutics, Inc.’s (the “Company”) participation at such events. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investors: Neha Krishnamohan, Artiva Biotherapeutics, ir@artivabio.com
Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com,
+1.858.344.8091
FAQ
When is Artiva Biotherapeutics (ARTV) presenting at the Jefferies London Healthcare Conference 2024?
How can investors watch Artiva Biotherapeutics' (ARTV) Jefferies Conference presentation?
What type of presentation will Artiva Biotherapeutics (ARTV) give at the Jefferies Conference 2024?
Will Artiva Biotherapeutics (ARTV) management be available for investor meetings at the Jefferies Conference?
